Antitumor mechanisms when pRb and p53 are genetically inactivated

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

pRb and p53 are the two major tumor suppressors. Their inactivation is frequent when cancers develop and their reactivation is rationale of most cancer therapeutics. When pRb and p53 are genetically inactivated, cells irreparably lose the antitumor mechanisms afforded by them. Cancer genome studies document recurrent genetic inactivation of RB1 and TP53, and the inactivation becomes more frequent in more advanced cancers. These findings may explain why more advanced cancers are more likely to resist current therapies. Finding successful treatments for more advanced and multi-therapy-resistant cancers will depend on finding antitumor mechanisms that remain effective when pRb and p53 are genetically inactivated. Here, we review studies that have begun to make progress in this direction.

Original languageEnglish (US)
Pages (from-to)4547-4557
Number of pages11
JournalOncogene
Volume34
Issue number35
DOIs
StatePublished - Dec 8 2014

Fingerprint

Neoplasms
Therapeutics
Genome

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Antitumor mechanisms when pRb and p53 are genetically inactivated. / Zhu, Liang; Lu, Z.; Zhao, Hongling.

In: Oncogene, Vol. 34, No. 35, 08.12.2014, p. 4547-4557.

Research output: Contribution to journalArticle

@article{2924555d522547438e34b0ad4572557c,
title = "Antitumor mechanisms when pRb and p53 are genetically inactivated",
abstract = "pRb and p53 are the two major tumor suppressors. Their inactivation is frequent when cancers develop and their reactivation is rationale of most cancer therapeutics. When pRb and p53 are genetically inactivated, cells irreparably lose the antitumor mechanisms afforded by them. Cancer genome studies document recurrent genetic inactivation of RB1 and TP53, and the inactivation becomes more frequent in more advanced cancers. These findings may explain why more advanced cancers are more likely to resist current therapies. Finding successful treatments for more advanced and multi-therapy-resistant cancers will depend on finding antitumor mechanisms that remain effective when pRb and p53 are genetically inactivated. Here, we review studies that have begun to make progress in this direction.",
author = "Liang Zhu and Z. Lu and Hongling Zhao",
year = "2014",
month = "12",
day = "8",
doi = "10.1038/onc.2014.399",
language = "English (US)",
volume = "34",
pages = "4547--4557",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "35",

}

TY - JOUR

T1 - Antitumor mechanisms when pRb and p53 are genetically inactivated

AU - Zhu, Liang

AU - Lu, Z.

AU - Zhao, Hongling

PY - 2014/12/8

Y1 - 2014/12/8

N2 - pRb and p53 are the two major tumor suppressors. Their inactivation is frequent when cancers develop and their reactivation is rationale of most cancer therapeutics. When pRb and p53 are genetically inactivated, cells irreparably lose the antitumor mechanisms afforded by them. Cancer genome studies document recurrent genetic inactivation of RB1 and TP53, and the inactivation becomes more frequent in more advanced cancers. These findings may explain why more advanced cancers are more likely to resist current therapies. Finding successful treatments for more advanced and multi-therapy-resistant cancers will depend on finding antitumor mechanisms that remain effective when pRb and p53 are genetically inactivated. Here, we review studies that have begun to make progress in this direction.

AB - pRb and p53 are the two major tumor suppressors. Their inactivation is frequent when cancers develop and their reactivation is rationale of most cancer therapeutics. When pRb and p53 are genetically inactivated, cells irreparably lose the antitumor mechanisms afforded by them. Cancer genome studies document recurrent genetic inactivation of RB1 and TP53, and the inactivation becomes more frequent in more advanced cancers. These findings may explain why more advanced cancers are more likely to resist current therapies. Finding successful treatments for more advanced and multi-therapy-resistant cancers will depend on finding antitumor mechanisms that remain effective when pRb and p53 are genetically inactivated. Here, we review studies that have begun to make progress in this direction.

UR - http://www.scopus.com/inward/record.url?scp=84940609750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940609750&partnerID=8YFLogxK

U2 - 10.1038/onc.2014.399

DO - 10.1038/onc.2014.399

M3 - Article

VL - 34

SP - 4547

EP - 4557

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 35

ER -